PTC Gambles On Success With Emflaza; Says Price Revision Is Needed

Looking to become a therapeutic area leader in DMD, PTC pays $140m up front for Marathon's controversial Emflaza, but the biotech's stock price plummeted, indicating that investors don't share PTC's optimism.